354 Stock Overview
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Collegium Pharmaceutical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.00 |
| 52 Week High | US$38.60 |
| 52 Week Low | US$23.20 |
| Beta | 0.95 |
| 11 Month Change | -8.23% |
| 3 Month Change | -13.69% |
| 1 Year Change | 22.88% |
| 33 Year Change | 84.71% |
| 5 Year Change | 48.72% |
| Change since IPO | 107.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 354 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3.6% | -1.0% | 0.2% |
| 1Y | 22.9% | -19.3% | 8.5% |
Return vs Industry: 354 exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: 354 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 354 volatility | |
|---|---|
| 354 Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 354 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 354's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 197 | Vikram Karnani | www.collegiumpharma.com |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. Fundamentals Summary
| 354 fundamental statistics | |
|---|---|
| Market cap | €927.86m |
| Earnings (TTM) | €85.08m |
| Revenue (TTM) | €575.45m |
10.9x
P/E Ratio1.6x
P/S RatioIs 354 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 354 income statement (TTM) | |
|---|---|
| Revenue | US$599.25m |
| Cost of Revenue | US$79.91m |
| Gross Profit | US$519.33m |
| Other Expenses | US$430.74m |
| Earnings | US$88.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.75 |
| Gross Margin | 86.66% |
| Net Profit Margin | 14.78% |
| Debt/Equity Ratio | 370.2% |
How did 354 perform over the long term?
See historical performance and comparison